Information Provided By: 
Fly News Breaks for July 25, 2017
GNCA
Jul 25, 2017 | 07:45 EDT
Stifel analyst Stephen D. Willey says that Phase 2b data showing that Genocea's f GEN-003 achieved its primary endpoint in treating genital herpes is positive. The analyst says any clarity into new funding for a Phase 3 development program "should help re-rate the stock to a valuation which more appropriately reflects the longer-term market opportunity." He keeps a $15 price target and a Buy rating on the stock.
News For GNCA From the Last 2 Days
There are no results for your query GNCA
